| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal NG101: Early and locally advanced breast cancer: diagnosis and management |
|
Medicine details |
|
| Medicine name | letrozole (Femara®) |
| Formulation | 2.5mg tablet |
| Reference number | 184 |
| Indication | Treatment of early invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/10/2005 |
| NICE guidance | NG101: Early and locally advanced breast cancer: diagnosis and management |